Abstract
Relapse is a threat in patients treated for acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) activity may affect the sensitivity of patients to folate-based chemotherapeutic drugs, thus influencing the relapse risk. Two polymorphisms of the gene encoding MTHFR, C677T and A1298C, alter MTHFR enzyme activity and may be associated with ALL relapse. The aim of this meta-analysis was to clarify the correlation between the C677T and A1298C polymorphisms and ALL relapse. To this end, data were collected from studies of the association between these two polymorphisms and ALL relapse. Analysis of the data revealed a serious contradiction among the results. A recessive model demonstrated that the ALL relapse risk was significantly increased in carriers of the 677 TT genotype, especially for pediatric ALL, but was unaffected by the A1298C polymorphism. These findings confirm that the MTHFR C677T polymorphism could be considered as a good marker of the pediatric ALL relapse risk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
De Mattia E, Toffoli G . C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009; 45: 1333–1351.
de Jonge R, Hooijberg JH, van Zelst BD, Jansen G, van Zantwijk CH, Kaspers GJ et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005; 106: 717–720.
Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301: 393–403.
Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35: 572–579.
Krajinovic M, Costea I, Chiasson S . Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359: 1033–1034.
Pui CH, Evans WE . Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178.
Thomas X, Le QH . Prognostic factors in adult acute lymphoblastic leukemia. Hematology 2003; 8: 233–242.
Cheok MH, Evans WE . Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6: 117–129.
Kishi S, Cheng C, French D, Pei D, Das S, Cook EH et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109: 4151–4157.
Bailey LB, Gregory JR . Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999; 129: 919–922.
Karas KN, Milek M, Jazbec J, Mlinaric-Rascan I . 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk Res 2009; 33: 1344–1348.
Eissa DS, Ahmed TM . C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 2013; 24: 181–188.
Safarinejad MR, Shafiei N, Safarinejad S . Methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C and G1793A polymorphisms: association with risk for clear cell renal cell carcinoma and tumour behaviour in men. Clin Oncol (R Coll Radiol) 2012; 24: 269–281.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–113.
Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis ER et al. The 1298A—>C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409–415.
Chiusolo P, Reddiconto G, Farina G, Mannocci A, Fiorini A, Palladino M et al. MTHFR polymorphisms’ influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 2007; 31: 1669–1674.
D'Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol 2011; 68: 1339–1346.
El-Khodary NM, El-Haggar SM, Eid MA, Ebeid EN . Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2012; 29: 2053–2062.
Tantawy AA, El-Bostany EA, Adly AA, Abou EAM, El-Ghouroury EA, Abdulghaffar EE . Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2010; 21: 28–34.
Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65: 2482–2487.
Sepe DM, McWilliams T, Chen J, Kershenbaum A, Zhao H, La M et al. Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer 2012; 58: 695–700.
Pietrzyk JJ, Bik-Multanowski M, Skoczen S, Kowalczyk J, Balwierz W, Alicja Chybicka et al. Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL. Leuk Res 2011; 35: 1464–1466.
Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105: 4752–4758.
Chiusolo P, Giammarco S, Bellesi S, Metafuni E, Piccirillo N, De Ritis D et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 2012; 69: 691–696.
Aldrin M, Raastad R, Tvete IF, Berild D, Frigessi A, Leegaard T et al. Antibiotic resistance in hospitals: a ward-specific random effect model in a low antibiotic consumption environment. Stat Med 2013; 32: 1407–1418.
Wang Y, Localio R, Rebbeck TR . Evaluating bias due to population stratification in case-control association studies of admixed populations. Genet Epidemiol 2004; 27: 14–20.
Wacholder S, Rothman N, Caporaso N . Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000; 92: 1151–1158.
Millikan RC . Re: population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2001; 93: 156–158.
Nachman J . Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 2005; 130: 166–173.
Rowe JM . Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol 2010; 150: 389–405.
Pui CH, Relling MV, Evans WE . Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15: 741–756.
Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A . Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4: 66–72.
Lobato-Mendizabal E, Lopez-Martinez B, Ruiz-Arguelles GJ . A critical review of the prognostic value of the nutritional status at diagnosis in the outcome of therapy of children with acute lymphoblastic leukemia. Rev Invest Clin 2003; 55: 31–35.
Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC . Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450–455.
Zheng M, Yue L, Zhang H, Yang C, Xie C . [Association of single nucleotide polymorphism of methylenetetrahydrofolate reductase gene with susceptibility to acute leukemia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2013; 30: 451–455.
Yang L, Hu X, Xu L . Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol 2012; 33: 1445–1454.
Tanaka Y, Manabe A, Nakadate H, Kondoh K, Nakamura K, Koh K et al. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients. Leuk Lymphoma, advance online publication, 3 September 2013 doi:10.3109/10428194.2013.825902(e-pub ahead of print).
Niedzielska E, Weclawek-Tompol J, Matkowska-Kocjan A, Chybicka A . The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate. Adv Clin Exp Med 2013; 22: 579–584.
Robien K, Ulrich CM . 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003; 157: 571–582.
Ongaro A, De Mattei M, Della PM, Rigolin G, Ambrosio C, Di Raimondo F et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 2009; 94: 1391–1398.
Rosenblatt DS . Methylenetetrahydrofolate reductase. Clin Invest Med 2001; 24: 56–59.
Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F et al. Effect of methylenetetrahydrofolate reductase 677C—>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103: 294–299.
Acknowledgements
This work was supported by the Fundamental Research Funds for the Central Universities (No. 08143047) of China.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
He, HR., Chen, SY., You, HS. et al. Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis. Pharmacogenomics J 14, 432–438 (2014). https://doi.org/10.1038/tpj.2014.10
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2014.10